Work Productivity/Interference and General Health Status Improvements with Sirukumab, an Anti-Il-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs: Results from the Phase 3 Sirround-D Study

Work Productivity ◽

General Health Status ◽

Phase 3 ◽

FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study

10.1136/annrheumdis-2017-eular.3597 ◽

2017 ◽

Author(s):

Y Tanaka ◽

D Aletaha ◽

S Peterson ◽

R Ganguly ◽

R Kurrasch ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Health Status ◽

General Health ◽

Work Productivity ◽

General Health Status ◽

Phase 3

AB0378 Improvements in Measures of Work Productivity/interference and General Health Status with Sirukumab Treatment in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.4335 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 1033.2-1034

Author(s):

T. Takeuchi ◽

G. Karpouzas ◽

C. Thorne ◽

K. McQuarrie ◽

S. Sheng ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Health Status ◽

Drug Treatment ◽

General Health ◽

Work Productivity ◽

General Health Status ◽

Disease Modifying ◽

Treatment Table ◽

Rheumatic Drug

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Sa1887 – General Health Status in Patients with Moderate to Severe Ulcerative Colitis Receiving Ustekinumab: Results from the Phase 3 Unifi Induction and Maintenance Studies

Gastroenterology ◽

10.1016/s0016-5085(19)37953-3 ◽

2019 ◽

Vol 156 (6) ◽

pp. S-442

Author(s):

Silvio Danese ◽

Bruce E. Sands ◽

Rupert W. Leong ◽

Hongyan Zhang ◽

Jewel Johanns ◽

...

Keyword(s):

Ulcerative Colitis ◽

Health Status ◽

General Health ◽

General Health Status ◽

Phase 3 ◽

Severe Ulcerative Colitis

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(18)31116-4 ◽

2018 ◽

Vol 391 (10139) ◽

pp. 2513-2524 ◽

Cited By ~ 119

Author(s):

Mark C Genovese ◽

Roy Fleischmann ◽

Bernard Combe ◽

Stephen Hall ◽

Andrea Rubbert-Roth ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Disease Modifying ◽

Randomised Controlled

P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjy222.530 ◽

2019 ◽

Vol 13 (Supplement_1) ◽

pp. S311-S312

Author(s):

S Danese ◽

B E Sands ◽

R W Leong ◽

H Zhang ◽

J Johanns ◽

...

Keyword(s):

Ulcerative Colitis ◽

Health Status ◽

General Health ◽

General Health Status ◽

Phase 3 ◽

Severe Ulcerative Colitis

Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)

Modern Rheumatology ◽

10.1080/14397595.2019.1639939 ◽

2019 ◽

Vol 30 (2) ◽

pp. 239-248 ◽

Cited By ~ 5

Author(s):

Hideto Kameda ◽

Kazuteru Wada ◽

Yoshinori Takahashi ◽

Owen Hagino ◽

Hubert van Hoogstraten ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Phase 3 ◽

AB0514 Efficacy and Safety of Tofacitinib in Chinese Patients with Active Rheumatoid Arthritis: Subgroup Analysis from a Phase 3 Study of Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.4278 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 1071-1071 ◽

Cited By ~ 2

Author(s):

Y. An ◽

Z. Li ◽

Q. Wu ◽

K. Kwok ◽

L. Wang

Keyword(s):

Rheumatoid Arthritis ◽

Subgroup Analysis ◽

Chinese Patients ◽

Efficacy And Safety ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Phase 3 ◽

SAT0167 Health-Related Physical and Emotional Well-Being and Fatigue Improve Significantly with Sirukumab Treatment: Results of A Phase 3 Study in Patients with Active Rheumatoid Arthritis Refractory To Conventional Disease-Modifying Anti-Rheumatic Drugs: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.4229 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 727.1-727

Author(s):

G. Karpouzas ◽

C. Thorne ◽

T. Takeuchi ◽

K. McQuarrie ◽

S. Sheng ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Well Being ◽

Treatment Results ◽

Phase 3 ◽

Health Related ◽

086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs

Rheumatology ◽

10.1093/rheumatology/kez106.085 ◽

2019 ◽

Vol 58 (Supplement_3) ◽

Author(s):

David Walker ◽

Mark C Genovese ◽

Kenneth Kalunian ◽

Jacques-Eric Gottenberg ◽

Kurt de Vlam ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Safety And Efficacy ◽